Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Hochster Shares Best Practices on Molecular Markers and Sequencing in Gastric Cancer

November 29th 2021

Howard S. Hochster, MD, discusses molecular markers for patients with gastric cancer, using gene expression profiles as biomarkers, and choosing between anti–PD-1 and anti–CTLA-4 agents.

Roychowdhury Relays Impact of Recent Infigratinib Approval in FGFR+ Cholangiocarcinoma

November 29th 2021

Sameek Roychowdhury, MD, PhD, discusses the pivotal phase 2 trial with infigratinib in FGFR-positive cholangiocarcinoma, the safety and efficacy achieved with infigratinib, and the next steps for this agent.

Experts Review Key Data From ESMO Congress 2021

November 29th 2021

Several leading experts discussed a variety of tumor types set to influence the next wave of investigative directions and change the standard of care for patients in abstracts at the European Society for Medical Oncology Congress 2021.

ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer

November 29th 2021

Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.

Frontline Cabozantinib Plus Atezolizumab Shows Favorable Survival in Advanced HCC

November 26th 2021

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

Katona Highlights the Hallmarks of Hereditary Diffuse Gastric Cancer

November 25th 2021

Bryson Katona, MD, discusses the hallmarks of hereditary diffuse gastric cancer.

Sequencing Systemic Therapy for Advanced HCC

November 24th 2021

Andrea Casadei Gardini, MD, leads the discussion on the optimal sequencing of systemic therapy for advanced HCC.

Optimizing the Selection of Frontline TKIs for Advanced HCC

November 24th 2021

Experts in gastroenterology share their approaches to first-line single-agent and combination TKI therapies for the treatment of advanced HCC.

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

November 23rd 2021

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Dr. Iqbal on the Emergence of Checkpoint Inhibitors in Upper GI Cancers

November 23rd 2021

Syma Iqbal, MD, discusses the emergence of checkpoint inhibitors in upper gastrointestinal cancers.

CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors

November 23rd 2021

AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.

Dr. Cohen on the Importance of Obtaining an Adequate Tissue Sample in GI Malignancies

November 22nd 2021

Steven J. Cohen, MD, discusses the importance of obtaining an adequate tissue sample for molecular testing in gastrointestinal cancers.

Dr. Hochster on Treatment Considerations for HER2+ Gastric Cancer

November 22nd 2021

Howard S. Hochster, MD, FACP, discusses treatment considerations for patients with HER2-positive gastric cancer.

ESMO 2021 Updates in Gastroesophageal and Gastric Adenocarcinomas

November 22nd 2021

Drs Sam Klempner, Nataliya V. Uboha, Daniel H. Ahn, and Manish A. Shah discuss recent data presented at ESMO 2021 for metastatic or locally advanced gastroesophageal and gastric adenocarcinomas.

Influx of Therapies in NETs Prompts Questions Over Combinations and Sequencing

November 19th 2021

Diane Reidy-Lagunes, MD, unpacked recent updates in neuroendocrine tumors.

Kalyan and Mouli Provide Perspective on the Power of Personalized Medicine in HCC

November 18th 2021

Dr. Kalyan and Dr. Mouli discuss the importance of multidisciplinary care in hepatocellular carcinoma, data regarding real-world personalization treatment recommendations, and the benefits of decision-making analysis tools in the space.

A New Frontier in Cholangiocarcinoma Management and Treatment

November 18th 2021

This content was developed in collaboration with Servier Pharmaceuticals and Onc Live

Dr. Li on the Interim Results of a Phase 1 Trial With Surufatinib in NETs

November 17th 2021

Daneng Li, MD, discusses the interim analysis results of a phase 1 trial evaluating surufatinib in United States patients with neuroendocrine tumors.

Updates to First-line Treatment Options for Advanced HCC

November 17th 2021

Andrea Casadei Gardini, MD, presents the case of a 63-year-old man diagnosed with advanced HCC, and the panel reviews available first-line treatment options for patients with advanced HCC.

Is There a Role for Systemic Therapy for Patients With Intermediate HCC?

November 17th 2021

Gastroenterology experts discuss whether there a is a role for systemic therapy for the management of intermediate HCC.